

Special Issue

Neurodegenerative Diseases: Molecular Pathology and Personalized Treatment

Message from the Guest Editor

This issue will highlight translational research and precision medicine approaches, including biomarker discovery, individualized risk assessment, and targeted therapeutic strategies, such as gene therapy, RNA-based treatments, neuroprotective agents, and personalized neuromodulation techniques. Studies integrating computational modelling, artificial intelligence, and machine learning to refine patient stratification and treatment prediction are welcome. Additionally, we seek investigations into disease heterogeneity, the role of sex and ageing in neurodegeneration, and novel clinical trial designs that address patient-specific responses to therapy. Contributions from interdisciplinary collaborations that bridge basic, translational, and clinical research are encouraged to provide a comprehensive understanding of disease mechanisms and the path toward more effective, individualized treatments. This Special Issue aims to drive forward the next generation of personalized interventions for neurodegenerative diseases.

Guest Editor

Dr. Oscar Arias-Carrion

Experimental Neurology, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City 14389, Mexico

Deadline for manuscript submissions

20 November 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/232496

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).